Company AstraZeneca and the University of Oxford announced the conclusion of an agreement on international development of recombinant adenovirus vaccine, developed by the University and designed to prevent infectious diseases COVID-19 caused by the virus SARS-CoV-2. In accordance with the agreement, AstraZeneca will be responsible for the development, production and distribution of vaccines around the world.
Based ChAdOx1 nCoV-19 developed by the Jenner Institute at Oxford University and the Oxford group to study vaccines lies a viral vector based on the adenovirus, which contains the genetic material of the spinous protein of SARS-CoV-2. After vaccination, the synthesis of spiky surface protein, which leads to the formation of an immune response to COVID-19 with possible subsequent infected by this virus.
Recombinant adenoviral vector (ChAdOx1) was selected due to the strong immune response upon introduction of a single dose. In addition, it is not replicated, therefore can not lead to persistent infection after vaccination. To date, vaccines based on virus ChAdOx1 was tested on a large group of people in excess of 320 people and showed that they are safe and well tolerated, although may cause temporary side effects such as fever, flu-like symptoms, headache or pain in the hands.
In five medical centers in the South of the UK was initiated clinical phase I studies in healthy volunteers aged 18 to 55 years to examine the safety and efficacy of the vaccine. The results of the first phase of the test can be obtained in may. The transition to the next phase of testing is planned for the middle of this year.